Section I. Drug Resistance Related Proteins and Glutathione.- 1. MDR1/P-gp Expression as a Prognostic Factor in Acute Leukemias.- 2. Clinical Significance of P-Glycoprotein (P-gp) Expression in Childhood Acute Lymphoblastic Leukemia: Results of a 6-Year Prospective Study.- 3. Prognostic Value of P-gp Expression and Related Function in Childhood Acute Leukemia.- 4. Comparison of P-Glycoprotein Expression and Function with in Vitro Sensitivity to Anthracyclines in AML.- 5. Quinine Improves Results of Intensive Chemotherapy (IC) in Myelodysplastic Syndromes (MDS) Expressing P-Glycoprotein (PGP): Updated Results of a Randomized Study.- 6. Treatment of Poor Prognosis AML Patients Using PSC833 (Valspodar) plus Mitoxantrone, Etoposide, and Cytarabine (PSC-MEC).- 7. Assessment of P-Glycoprotein Expression by Immunocytochemistry and Flow Cytometry Using Two Different Monoclonal Antibodies Coupled with Functional Efflux Analysis in 34 Patients with Acute Myeloid Leukemia.- 8. Preliminary Immunocytochemical Studies of MDR-1 and MDR-3 Pgp Expression in B-Cell Leukaemias.- 9. A Mutation in the Promoter of the Multidrug Resistance Gene (MDR 1) in Human Hematological Malignancies May Contribute to the Pathogenesis of Resistant Disease.- 10. Reproducible Flow Cytometric Methodology for Measuring Multidrug Resistance in Leukaemic Blasts.- 11. Natural Fluorescence Imaging of Leukemic Cells for Studying Uptake and Retention of Anthracyclines.- 12. Artificial Neural Networks as Versatile Tools for Prediction of MDR-Modulatory Activity.- 13. Discordance of P-Glycoprotein Expression and Function in Acute Leukemia.- 14. Multidrug Resistance Related Proteins in Primary Cutaneous Lymphomas.- 15. The Lung Resistance Protein (LRP) Predicts Poor Outcome in Acute Myeloid Leukemia.- 16. MRP Expression in Acute Myeloid Leukemia: An Update.- 17. Evidence for Functional Discrimination between Leukemic Cells Overexpressing Multidrug-Resistance Associated Protein and P-Glycoprotein.- 18. Both Pgp and MRP1 Activities Using Calcein-AM Contribute to Drug Resistance in AML.- 19. Absolute Levels of MDR-1, MRP, and BCL-2 mRNA and Tumor Remission in Acute Leukemia.- 20. Multidrug Resistance Protein MRP1, Glutathione, and Related Enzymes: Their Importance in Acute Myeloid Leukemia.- 21. Glutathione and the Regulation of Cell Death.- 22. Evidence for the Involvement of the Glutathione Pathway in Drug Resistance in AML.- 23. Glutathione in Childhood Acute Leukaemias.- Section II. Apoptosis and Cell Death Regulations.- 24. Apoptosis: Molecules and Mechanisms.- 25. Activation of Apoptosis Pathways by Anticancer Drugs.- 26. BCL-2 Stimulates Apoptin®-Induced Apoptosis.- 27. CD95 (Fas/Apo-1) Antigen Is a New Prognostic Marker of Blast Cells of Acute Lymphoblastic Leukaemia Patients.- 28. Inhibition of Fas/Fas-Ligand Does Not Block Chemotherapy-Induced Apoptosis in Drug Sensitive and Resistant Cells.- 29. Effects of PARP Inhibition on Drug and FAS-Induced Apoptosis in Leukaemic Cells.- 30. Apoptotic Fraction in Childhood ALL Assessed by DNA in Situ Labelling Is Ploidy Independent.- 31. PCNA Bearing Structures Are Retained in Apoptotic Phase of Childhood ALL Cell Cycle.- 32. Apoptosis Corrected Proliferation Fraction in Childhood ALL Is Related to Karyotype.- 33. Proliferation and Apoptosis Does Not Affect Presenting White Cell Count in Childhood ALL.- 34. Apoptosis by Anthracyclines at Therapeutic Concentrations in MDR1+ Human Leukemic Cells.- 35. BCL-2 Expression in Childhood Leukemia versus Spontaneous Apoptosis, Drug Induced Apoptosis and in Vitro Drug Resistance.- 36. Comparison of BCL-2 and Bax Protein Expression with in Vitro Sensitivity to Ara-C and 6TG in AML.- 37. Synthetic Cyclin Dependent Kinase Inhibitors: New Generation of Potent Anti-Cancer Drugs.- 38. Factors Contributing to the Resistance to Apoptosis Induced by Topoisomerase I Inhibitors in Vincristine Resistant Cells.- 39. Two Distinct Modes of Oncoprotein Expression during Apoptosis Resistance in Vincris
Cellular drug resistance is a major limitation to the success of chemotherapy of leu kemia and lymphoma. The importance of this has now been recognized by both clinicians and scientists. It is of utmost importance to bridge the gap between laboratory and clinic in this field of research. This is the main purpose of the series of International Symposia on Drug Resistance in Leukemia and Lymphoma. These are held every three years in Am sterdam, The Netherlands, since 1992. This book contains the proceedings of the third of these meetings, organised in 1998. The book covers all important aspects of drug resistance in leukemia and lymphoma, both in the form of extensive reviews as in manuscripts describing original data. General mechanisms of resistance are discussed, including the drug resistance related proteins p glycoprotein, MRP (multi-drug resistance protein) and LRP (lung resistance protein), and the role of glutathione and glutathione-S-transferases. Moreover, more drug type-specific mechanisms of resistance are a topic, such as for glucocorticoids and antifolates. Much in formation is provided on apoptosis and its regulators, and on the results of cell culture drug resistance assays. Several papers focus on the modulation or circumvention of drug resistance.
Springer Book Archives